Roche’s R&D is moving on up. The pharma giant has opened two new high-rises in Basel, Switzerland, according to a Sept. 10 release. The facility is named the Pharma Research and Early Development (pRED) Center and houses about 1,000 state-of-the-art laboratory and office workplaces.

Just a few short weeks after winning an FDA Fast Track tag for its investigational BTK degrader in certain blood cancers, BeiGene has been accused of trade secrets theft by its old oncology rival AbbVie.

BridgeBio Pharma is slashing its gene therapy budget and pulling back from the modality after seeing the results of a phase 1/2 clinical trial. CEO Neil Kumar, Ph.D., said the data “are not yet transformational,” driving BridgeBio to shift its focus to other drug candidates and ways to treat disease.

SpectraWAVE has raised $50 million to support its approach to imaging the insides of clogged, plaque-filled blood vessels.

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the likes of Moderna and BioNTech.

Genesis Therapeutics’ shiny AI drug discovery platform GEMS is catching on, having now caught the eye of Gilead Sciences.

Johnson & Johnson is collating its pantheon of medtech brands under a single banner, to further simplify the company’s presentation.

With a strong track record for identifying diamonds in the rough, Bain Capital Life Sciences (BCLS) has become a powerful force in biotech investing, pulling in more funding for each of its big-money rounds.

Gentronix, a British contract research organization that specializes in genetic toxicology, is officially off the market. Danish CRO Scantox, with its majority owner Impilo, bought Gentronix and integrated the company into its toxicology operations, according to a Sept. 9 release.

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to question whether the biotech has done enough to differentiate its asset and unseat the incumbent.